Table 2.
Univariable and multivariate analyses for overall survival, disease–free survival, and relapse
| Overall survivala | Disease–free survivala | Cumulative incidence of relapseb | ||||
|---|---|---|---|---|---|---|
| Univariate HR (95% CI); p |
Multivariate HR (95% CI); p |
Univariate HR (95% CI); p |
Multivariate HR (95% CI); p |
Univariate HR (95% CI); p |
Multivariate HR (95% CI); p |
|
| Sex, male vs female | 1.15 (0.86–1.54); 0.35 | – | 1.10 (0.84–1.43); 0.50 | – | 1.08 (0.79–1.47); 0.65 | – |
| Age, >36 years vs ≤36 years | 1.24 (0.92–1.66); 0.16 | – | 1.19 (0.91–1.56); 0.19 | – | 1.11 (0.81–1.52); 0.51 | – |
| WBC, >53 × 109/L vs ≤ 53 × 109/L | 1.09 (0.81–1.46); 0.59 | – | 1.10 (0.84–1.44); 0.48 | – | 1.09 (0.80–1.49); 0.60 | – |
| Transplant modality | 0.70 | – | 0.56 | – | 0.37 | – |
| MSD | 1 | – | 1 | – | 1 | – |
| MUD | 1.34 (0.67–2.67); 0.41 | – | 1.39 (0.76–2.55); 0.28 | – | 1.61 (0.83–3.13); 0.16 | – |
| HID | 1.09 (0.73–1.62); 0.67 | – | 1.08 (0.76–1.53); 0.67 | – | 1.15 (0.77–1.72); 0.51 | – |
| ELN risk stratification | 0.0052 | 0.044 | 0.00053 | 0.0073 | 0.00072 | 0.0018 |
| Favorable | 1 | 1 | 1 | 1 | 1 | 1 |
| Intermediate | 1.77 (1.12–2.81); 0.015 | 1.78 (1.11–2.84); 0.016 | 1.85 (1.21–2.82); 0.0047 | 1.90 (1.23–2.92); 0.0036 | 1.96 (1.18–3.27); 0.010 | 2.04 (1.23–3.41); 0.0061 |
| Adverse | 2.20 (1.42–3.41); 0.00040 | 1.87 (1.16–3.03); 0.011 | 2.19 (1.46–3.28); 0.00014 | 2.11 (1.35–3.30); 0.0011 | 2.38 (1.46–3.86); 0.00048 | 2.40 (1.47–3.90);0.00043 |
| Unknown | 1.89 (1.16–3.09); 0.011 | 1.26 (0.60–2.66); 0.55 | 2.34 (1.51–3.63); 0.00015 | 2.05 (1.00–4.21); 0.052 | 2.81 (1.68–4.70); <0.0001 | 2.56 (1.53–4.29); 0.00037 |
| Allelic ratio, ≥ 0.5 vs < 0.5 | 1.66 (1.18–2.34); 0.0040 | 1.35 (0.91–1.99); 0.13 | 1.41 (1.30–1.94); 0.032 | 1.09 (0.76–1.55); 0.64 | 1.29 (0.89–1.86); 0.18 | – |
| Pre-transplantation sorafenib, used vs not used | 0.74 (0.55–0.99); 0.043 | 0.73 (0.54–0.99); 0.041 | 0.70 (0.54–0.92); 0.011 | 0.71 (0.54–0.94); 0.015 | 0.68 (0.49–0.93); 0.015 | 0.69 (0.50–0.94); 0.019 |
| Post-transplantation sorafenib, used vs not used | 0.50 (0.37–0.69); <0.0001 | 0.52 (0.38–0.72); <0.0001 | 0.48 (0.36–0.64); <0.0001 | 0.50 (0.37–0.67); <0.0001 | 0.47 (0.33–0.66); <0.0001 | 0.50 (0.35–0.70); 0.00062 |
aResults of COX regression analyses
bResults of competing risk regression analyses